Residency · Residency · Nuclear Medicine
FDG PET/CT in Head and Neck Cancer
Overview
FDG PET/CT is integral to the management of head and neck squamous cell carcinoma (HNSCC), playing important roles in staging, restaging, and treatment response assessment. It is particularly valuable for detection of unknown primary tumors, nodal staging, and post-treatment surveillance. Metabolic imaging complements the anatomic assessment provided by CT and MRI in a region with complex anatomy where distinguishing post-treatment changes from recurrent disease is often challenging.
Indications
Initial Staging
FDG PET/CT is used to evaluate the locoregional extent and distant metastases in advanced-stage HNSCC (stage III and IV). It detects synchronous second primary malignancies, which are reported in 5 to 10% of cases, a particularly important consideration in patients with a history of tobacco and alcohol use. PET/CT also improves assessment of cervical lymph node involvement beyond what clinical examination and CT or MRI can provide.
Unknown Primary Tumor
PET/CT detects the primary site in approximately 25 to 55% of patients presenting with cervical nodal metastases from an unknown primary. It guides directed biopsy, reducing the need for extensive pan-endoscopy with random biopsies. The most commonly identified primary sites are the palatine tonsil and base of tongue.
Post-Treatment Assessment
The optimal timing for post-treatment PET/CT is at least 12 weeks after completion of chemoradiation to minimize false-positive results from treatment-related inflammation. Earlier imaging at 8 to 10 weeks has a higher false-positive rate due to ongoing mucosal inflammation and radiation edema.
<image>FDG PET/CT showing intense uptake in a left tonsillar primary with ipsilateral level II lymph node metastasis in HNSCC staging</image>
Interpretation: Hopkins Criteria (NI-RADS Adjacent)
Five-Point Scale for Post-Treatment Response
The Hopkins criteria provide a standardized five-point scale for interpreting post-treatment PET/CT. Score 1 shows focal uptake less than the internal jugular vein, indicating complete metabolic response. Score 2 shows focal uptake greater than the internal jugular vein but less than the liver. Score 3 shows diffuse uptake greater than the internal jugular vein, which is likely post-treatment inflammation. Score 4 shows focal uptake greater than the liver, which is likely residual disease. Score 5 shows focal and intense uptake markedly greater than the liver, indicating definite residual disease.
| Hopkins Score | Uptake Level | Interpretation | Management |
|---|---|---|---|
| 1 | Focal uptake < internal jugular vein | Complete metabolic response | Observation |
| 2 | Focal uptake > IJV but < liver | Likely complete response | Observation |
| 3 | Diffuse uptake > IJV | Likely post-treatment inflammation | Observation/follow-up |
| 4 | Focal uptake > liver | Likely residual disease | Biopsy/intervention |
| 5 | Focal intense uptake >> liver | Definite residual disease | Biopsy/intervention |
Application
Scores 1 through 3 are generally managed with observation and follow-up imaging. Scores 4 and 5 warrant biopsy or further intervention. The high negative predictive value, exceeding 95%, allows confident surveillance when the score is 1 or 2.
<image>Hopkins criteria scoring examples showing post-treatment PET/CT appearances from score 1 (complete response) through score 5 (definite residual disease)</image>
Normal Variants and Pitfalls
Physiologic Uptake
Several normal structures in the head and neck demonstrate physiologic FDG uptake that must not be misinterpreted as disease. Waldeyer ring (palatine tonsils, lingual tonsils, and adenoids) shows symmetric moderate FDG uptake. Vocal cord uptake can occur from speaking during the uptake period, and patients should be instructed to remain silent. The salivary glands (parotid, submandibular, and sublingual) demonstrate low-grade physiologic uptake. The muscles of mastication and tongue can show asymmetric uptake from chewing or tension.
False Positives
Post-radiation mucositis and soft tissue edema produce significant uptake, especially when imaging is performed less than 12 weeks after treatment. Reactive lymph nodes, osteoradionecrosis of the mandible, brown fat uptake in the neck (supraclavicular and posterior cervical triangle), infection or abscess formation, and benign salivary gland tumors such as Warthin tumors and pleomorphic adenomas of the parotid can all cause false-positive results.
False Negatives
Small primary tumors below 1 cm may fall below PET spatial resolution. Superficial mucosal lesions can be missed. Tumors with low FDG avidity, such as well-differentiated or low-grade lesions, may not accumulate sufficient tracer. Elevated blood glucose levels reduce tumor uptake and can cause false-negative results.
Nasopharyngeal Carcinoma (NPC) Considerations
PET/CT is highly sensitive for nodal staging in nasopharyngeal carcinoma, especially for detecting retropharyngeal nodes that are difficult to assess by other means. It is useful for identifying distant metastases at initial staging in the bone, liver, and lung. Post-treatment PET/CT at 12 weeks has a high negative predictive value for local and regional control. Epstein-Barr virus DNA titers complement PET/CT for disease monitoring.
<image>PET/CT in nasopharyngeal carcinoma demonstrating primary tumor uptake with bilateral retropharyngeal and cervical nodal involvement</image>
Technical Considerations
Standard patient preparation includes fasting for at least 4 to 6 hours with blood glucose below 200 mg/dL. Patients must be instructed not to talk, chew, or suck on candy during the uptake period to minimize muscular uptake in the head and neck. Arms-down positioning may be needed for head and neck-focused protocols. Dedicated neck imaging with thin-slice CT reconstructions improves anatomic correlation with PET findings.
Role of PET/CT in Treatment Planning
FDG PET/CT is used in radiation therapy planning for biologically targeted volume delineation. Gross tumor volume (GTV) is defined using SUV thresholds, commonly SUV 2.5 or 40% of SUVmax. Adaptive radiation planning based on mid-treatment PET response is an evolving approach. PET identifies high-risk volumes for radiation dose escalation and can help spare uninvolved tissues.
<image>PET/CT-guided radiation therapy planning showing GTV delineation overlaid on the PET/CT fusion image for an oropharyngeal carcinoma</image>
Clinical Pearls
PET/CT findings should always be compared with direct endoscopic examination and tissue sampling. The imaging findings alone are not sufficient for definitive diagnosis.
The 12-week post-treatment scan timing is critical. Earlier imaging leads to unnecessary biopsies due to treatment-related inflammatory uptake.
Asymmetric tonsillar uptake should raise suspicion even when subtle, especially in the context of HPV-related oropharyngeal cancer.
For the workup of an unknown primary, PET/CT should be performed before any biopsy or tonsillectomy to avoid post-procedural inflammation that can obscure the primary site.
Distant metastatic disease is present in approximately 10 to 15% of stage IV HNSCC at initial staging, making whole-body PET/CT essential.
References
- Stable, L. A., et al. "Hopkins Criteria for PET/CT Response Assessment in Head and Neck Cancer." Radiology, 2015.
- NCCN Guidelines: Head and Neck Cancers -- Imaging Recommendations.
- Stable, R. L., et al. "FDG PET/CT in Head and Neck Squamous Cell Carcinoma." Journal of Nuclear Medicine, 2020.
- ACR Appropriateness Criteria: Head and Neck Cancer Staging and Surveillance.
